These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1096 related articles for article (PubMed ID: 32085836)

  • 1. Safety and efficacy of GABA
    Chabriat H; Bassetti CL; Marx U; Audoli-Inthavong ML; Sors A; Lambert E; Wattez M; Hermann DM;
    Lancet Neurol; 2020 Mar; 19(3):226-233. PubMed ID: 32085836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized Efficacy and Safety Trial with Oral S 44819 after Recent ischemic cerebral Event (RESTORE BRAIN study): a placebo controlled phase II study.
    Chabriat H; Bassetti CL; Marx U; Picarel-Blanchot F; Sors A; Gruget C; Saba B; Wattez M; Audoli ML; Hermann DM
    Trials; 2020 Feb; 21(1):136. PubMed ID: 32014032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of natalizumab in patients with acute ischaemic stroke (ACTION): a randomised, placebo-controlled, double-blind phase 2 trial.
    Elkins J; Veltkamp R; Montaner J; Johnston SC; Singhal AB; Becker K; Lansberg MG; Tang W; Chang I; Muralidharan K; Gheuens S; Mehta L; Elkind MSV
    Lancet Neurol; 2017 Mar; 16(3):217-226. PubMed ID: 28229893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of multipotent adult progenitor cells in acute ischaemic stroke (MASTERS): a randomised, double-blind, placebo-controlled, phase 2 trial.
    Hess DC; Wechsler LR; Clark WM; Savitz SI; Ford GA; Chiu D; Yavagal DR; Uchino K; Liebeskind DS; Auchus AP; Sen S; Sila CA; Vest JD; Mays RW
    Lancet Neurol; 2017 May; 16(5):360-368. PubMed ID: 28320635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of desmoteplase given 3-9 h after ischaemic stroke in patients with occlusion or high-grade stenosis in major cerebral arteries (DIAS-3): a double-blind, randomised, placebo-controlled phase 3 trial.
    Albers GW; von Kummer R; Truelsen T; Jensen JK; Ravn GM; Grønning BA; Chabriat H; Chang KC; Davalos AE; Ford GA; Grotta J; Kaste M; Schwamm LH; Shuaib A;
    Lancet Neurol; 2015 Jun; 14(6):575-84. PubMed ID: 25937443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial.
    Sharma M; Molina CA; Toyoda K; Bereczki D; Bangdiwala SI; Kasner SE; Lutsep HL; Tsivgoulis G; Ntaios G; Czlonkowska A; Shuaib A; Amarenco P; Endres M; Yoon BW; Tanne D; Toni D; Yperzeele L; von Weitzel-Mudersbach P; Sampaio Silva G; Avezum A; Dawson J; Strbian D; Tatlisumak T; Eckstein J; Ameriso SF; Weber JR; Sandset EC; Goar Pogosova N; Lavados PM; Arauz A; Gailani D; Diener HC; Bernstein RA; Cordonnier C; Kahl A; Abelian G; Donovan M; Pachai C; Li D; Hankey GJ
    Lancet Neurol; 2024 Jan; 23(1):46-59. PubMed ID: 38101902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus ventilator-associated pneumonia (SAATELLITE): a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trial.
    François B; Jafri HS; Chastre J; Sánchez-García M; Eggimann P; Dequin PF; Huberlant V; Viña Soria L; Boulain T; Bretonnière C; Pugin J; Trenado J; Hernandez Padilla AC; Ali O; Shoemaker K; Ren P; Coenjaerts FE; Ruzin A; Barraud O; Timbermont L; Lammens C; Pierre V; Wu Y; Vignaud J; Colbert S; Bellamy T; Esser MT; Dubovsky F; Bonten MJ; Goossens H; Laterre PF;
    Lancet Infect Dis; 2021 Sep; 21(9):1313-1323. PubMed ID: 33894131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of the Selective α5-GABAAR Antagonist S44819 on Excitability in the Human Brain: A TMS-EMG and TMS-EEG Phase I Study.
    Darmani G; Zipser CM; Böhmer GM; Deschet K; Müller-Dahlhaus F; Belardinelli P; Schwab M; Ziemann U
    J Neurosci; 2016 Dec; 36(49):12312-12320. PubMed ID: 27927951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial.
    Hill MD; Goyal M; Menon BK; Nogueira RG; McTaggart RA; Demchuk AM; Poppe AY; Buck BH; Field TS; Dowlatshahi D; van Adel BA; Swartz RH; Shah RA; Sauvageau E; Zerna C; Ospel JM; Joshi M; Almekhlafi MA; Ryckborst KJ; Lowerison MW; Heard K; Garman D; Haussen D; Cutting SM; Coutts SB; Roy D; Rempel JL; Rohr AC; Iancu D; Sahlas DJ; Yu AYX; Devlin TG; Hanel RA; Puetz V; Silver FL; Campbell BCV; Chapot R; Teitelbaum J; Mandzia JL; Kleinig TJ; Turkel-Parrella D; Heck D; Kelly ME; Bharatha A; Bang OY; Jadhav A; Gupta R; Frei DF; Tarpley JW; McDougall CG; Holmin S; Rha JH; Puri AS; Camden MC; Thomalla G; Choe H; Phillips SJ; Schindler JL; Thornton J; Nagel S; Heo JH; Sohn SI; Psychogios MN; Budzik RF; Starkman S; Martin CO; Burns PA; Murphy S; Lopez GA; English J; Tymianski M;
    Lancet; 2020 Mar; 395(10227):878-887. PubMed ID: 32087818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-immunogenic recombinant staphylokinase versus alteplase for patients with acute ischaemic stroke 4·5 h after symptom onset in Russia (FRIDA): a randomised, open label, multicentre, parallel-group, non-inferiority trial.
    Gusev EI; Martynov MY; Nikonov AA; Shamalov NA; Semenov MP; Gerasimets EA; Yarovaya EB; Semenov AM; Archakov AI; Markin SS;
    Lancet Neurol; 2021 Sep; 20(9):721-728. PubMed ID: 34418399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): a phase 3, randomised, open-label, blinded endpoint trial.
    Logallo N; Novotny V; Assmus J; Kvistad CE; Alteheld L; Rønning OM; Thommessen B; Amthor KF; Ihle-Hansen H; Kurz M; Tobro H; Kaur K; Stankiewicz M; Carlsson M; Morsund Å; Idicula T; Aamodt AH; Lund C; Næss H; Waje-Andreassen U; Thomassen L
    Lancet Neurol; 2017 Oct; 16(10):781-788. PubMed ID: 28780236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stroke treatment with alteplase given 3.0-4.5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial.
    Bluhmki E; Chamorro A; Dávalos A; Machnig T; Sauce C; Wahlgren N; Wardlaw J; Hacke W
    Lancet Neurol; 2009 Dec; 8(12):1095-102. PubMed ID: 19850525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intensive blood pressure reduction with intravenous thrombolysis therapy for acute ischaemic stroke (ENCHANTED): an international, randomised, open-label, blinded-endpoint, phase 3 trial.
    Anderson CS; Huang Y; Lindley RI; Chen X; Arima H; Chen G; Li Q; Billot L; Delcourt C; Bath PM; Broderick JP; Demchuk AM; Donnan GA; Durham AC; Lavados PM; Lee TH; Levi C; Martins SO; Olavarria VV; Pandian JD; Parsons MW; Pontes-Neto OM; Ricci S; Sato S; Sharma VK; Silva F; Song L; Thang NH; Wardlaw JM; Wang JG; Wang X; Woodward M; Chalmers J; Robinson TG;
    Lancet; 2019 Mar; 393(10174):877-888. PubMed ID: 30739745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study.
    McClung MR; O'Donoghue ML; Papapoulos SE; Bone H; Langdahl B; Saag KG; Reid IR; Kiel DP; Cavallari I; Bonaca MP; Wiviott SD; de Villiers T; Ling X; Lippuner K; Nakamura T; Reginster JY; Rodriguez-Portales JA; Roux C; Zanchetta J; Zerbini CAF; Park JG; Im K; Cange A; Grip LT; Heyden N; DaSilva C; Cohn D; Massaad R; Scott BB; Verbruggen N; Gurner D; Miller DL; Blair ML; Polis AB; Stoch SA; Santora A; Lombardi A; Leung AT; Kaufman KD; Sabatine MS;
    Lancet Diabetes Endocrinol; 2019 Dec; 7(12):899-911. PubMed ID: 31676222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An injectable implant to stimulate the sphenopalatine ganglion for treatment of acute ischaemic stroke up to 24 h from onset (ImpACT-24B): an international, randomised, double-blind, sham-controlled, pivotal trial.
    Bornstein NM; Saver JL; Diener HC; Gorelick PB; Shuaib A; Solberg Y; Thackeray L; Savic M; Janelidze T; Zarqua N; Yarnitsky D; Molina CA;
    Lancet; 2019 Jul; 394(10194):219-229. PubMed ID: 31133406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Indobufen versus aspirin in patients with acute ischaemic stroke in China (INSURE): a randomised, double-blind, double-dummy, active control, non-inferiority trial.
    Pan Y; Meng X; Yuan B; Johnston SC; Li H; Bath PM; Dong Q; Xu A; Jing J; Lin J; Jiang Y; Xie X; Jin A; Suo Y; Yang H; Feng Y; Zhou Y; Liu Q; Li X; Liu B; Zhu H; Zhao J; Huang X; Li H; Xiong Y; Li Z; Wang Y; Zhao X; Liu L; Wang Y;
    Lancet Neurol; 2023 Jun; 22(6):485-493. PubMed ID: 37121237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of intra-arterial bone marrow mononuclear cell transplantation in patients with acute ischaemic stroke in Spain (IBIS trial): a phase 2, randomised, open-label, standard-of-care controlled, multicentre trial.
    Moniche F; Cabezas-Rodriguez JA; Valverde R; Escudero-Martinez I; Lebrato-Hernandez L; Pardo-Galiana B; Ainz L; Medina-Rodriguez M; de la Torre J; Escamilla-Gomez V; Ortega-Quintanilla J; Zapata-Arriaza E; de Albóniga-Chindurza A; Mancha F; Gamero MA; Perez S; Espinosa-Rosso R; Forero-Diaz L; Moya M; Piñero P; Calderón-Cabrera C; Nogueras S; Jimenez R; Martin V; Delgado F; Ochoa-Sepúlveda JJ; Quijano B; Mata R; Santos-González M; Carmona-Sanchez G; Herrera C; Gonzalez A; Montaner J
    Lancet Neurol; 2023 Feb; 22(2):137-146. PubMed ID: 36681446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial.
    Chupp GL; Bradford ES; Albers FC; Bratton DJ; Wang-Jairaj J; Nelsen LM; Trevor JL; Magnan A; Ten Brinke A
    Lancet Respir Med; 2017 May; 5(5):390-400. PubMed ID: 28395936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial.
    Shoamanesh A; Mundl H; Smith EE; Masjuan J; Milanov I; Hirano T; Agafina A; Campbell B; Caso V; Mas JL; Dong Q; Turcani P; Christensen H; Ferro JM; Veltkamp R; Mikulik R; De Marchis GM; Robinson T; Lemmens R; Stepien A; Greisenegger S; Roine R; Csiba L; Khatri P; Coutinho J; Lindgren AG; Demchuk AM; Colorado P; Kirsch B; Neumann C; Heenan L; Xu L; Connolly SJ; Hart RG;
    Lancet; 2022 Sep; 400(10357):997-1007. PubMed ID: 36063821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.
    Maher TM; Corte TJ; Fischer A; Kreuter M; Lederer DJ; Molina-Molina M; Axmann J; Kirchgaessler KU; Samara K; Gilberg F; Cottin V
    Lancet Respir Med; 2020 Feb; 8(2):147-157. PubMed ID: 31578169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 55.